一般演題（口演）15 EGFR遺伝子変異陽性肺癌（臨床試験）

[O15-3] Subcutaneous amivantamab vs intravenous amivantamab in EGFR-mutated, advanced NSCLC

^○Hiroaki Akamatsu¹, Natasha B Leighl², Sun Min Lim³, Ying Cheng⁴, Anna R Minchom⁵, Melina E Marmarelis⁶, Rachel E Sanborn⁷, James Chih-Hsin Yang⁸, Baogang Liu⁹, Thomas John¹⁰, Bartomeu Massuti¹¹, Alexander I. Spira¹², John Xie¹³, Debopriya Ghosh¹⁴, Ali Alhadab¹⁵, Remy B Verheijen¹⁶, Mohamed Gamil¹⁷, Joshua M Bauml¹⁸, Mahadi Baig¹⁹, Antonio Passaro²⁰ (1.Wakayama Medical University, 2.Princess Margaret Cancer Centre, Toronto, ON, Canada, 3.Yonsei University College of Medicine, Seoul, South Korea, 4.Jilin Cancer Hospital, Changchun, China, 5.The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK, 6.Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 7.Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA, 8.National Taiwan University Cancer Center, Taipei, Taiwan, 9.Harbin Medical University Cancer Hospital, Harbin, China, 10.Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia, 11.Alicante University Dr. Balmis Hospital, ISABIAL, Alicante, Spain, 12.Virginia Cancer Specialists, Fairfax, VA, USA, 13.Janssen Research ＆ Development, Raritan, NJ, USA, 14.Janssen Research ＆ Development, Raritan, NJ, USA, 15.Janssen Research ＆ Development, San Diego, CA, USA, 16.Janssen Research ＆ Development, Leiden, The Netherlands, 17.Janssen Research ＆ Development, Spring House, PA, USA, 18.Janssen Research ＆ Development, Spring House, PA, USA, 19.Janssen Research ＆ Development, Raritan, NJ, USA, 20.European Institute of Oncology IRCCS, Milano, Italy)

アンコール演題